European Society of Cardiology

# May Measurement Month 2018: an analysis of blood pressure screening results from Italy 

Camilla Torlasco ${ }^{1,2}$, Andrea Faini ${ }^{1}$, Claudio Ferri ${ }^{3}$, Guido Grassi ${ }^{4,2}$, Massimo Salvetti ${ }^{5,6}$, Maurizio Destro ${ }^{7}$, Arrigo F.G. Cicero ${ }^{8}$, Ferruccio Galletti ${ }^{9}{ }^{9} 10$, Lorenzo Ghiadoni ${ }^{11}$, Stefano Carugo ${ }^{12,13}$, Riccardo Sarzani ${ }^{14,15}$, Pietro Minuz ${ }^{16}$, Alberto Morganti ${ }^{17}$, Paolo Mulatero ${ }^{18}$, Giuseppe Mulè ${ }^{19}$, Carmine Savoia ${ }^{20}$, Massimo Volpe ${ }^{21,25}$, Claudio Borghi ${ }^{22}$, Thomas Beaney ${ }^{23,24}$, Anca Chis Ster ${ }^{23}$, Neil R. Poulter ${ }^{23}$, Xin Xia ${ }^{23}$, and Gianfranco Parati (1) ${ }^{1,2 *}$<br>${ }^{1}$ Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, IRCCS, San Luca Hospital, Piazzale Brescia 20, Milan 20149, Italy;<br>${ }^{2}$ Department of Medicine and Surgery, University of Milan-Bicocca, Piazza dell'Ateneo Nuovo 1, 20126 Milan, Italy;<br>${ }^{3}$ Department of Life, Health and Environmental Sciences, University of L'Aquila, piazza Santa Margherita 2, 67100, L'Aquila, Italy;<br>${ }^{4}$ Policlinico di Monza, Via Amati, 111-20900, Monza, Italy;<br>${ }^{5}$ Department of Clinical \& Experimental Sciences and Postgraduate School of Emergency \& Urgency Medicine, University of Brescia, Via Amati, 111-20900, Brescia, Italy;<br>${ }^{6}$ 2a Medicina-ASST Spedali Civili Brescia, Piazzale Spedali Civili, 1 25123, Brescia, Italy;<br>${ }^{7}$ Medical Science, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047, Treviglio, Italy;<br>${ }^{8}$ Medical and Surgical Sciences Department, University of Bologna, Via Zamboni, 33, 40126, Bologna, Italy;<br>${ }^{9}$ Department of Clinical Medicine and Surgery, ESH Excellence Center of Hypertension, Naples, Via Pansini, 5-80131, Italy;<br>${ }^{10}$ "Federico II" University of Naples Medical School, Corso Umberto I 40, Naples, 80138, Italy;<br>${ }^{11}$ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Lungarno Antonio Pacinotti, 43, 56121, Italy;<br>${ }^{12}$ Division of Cardiology, San Paolo University Hospital, Via Antonio di Rudini, 8, 20142, Milan, Italy;<br>${ }^{13}$ Department of Health Sciences, University of Milan, ia Festa del Perdono, 7, 20122, Milan, Italy;<br>${ }^{14}$ Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Via Festa del Perdono, 7, 20122, Ancona, Italy;<br>${ }^{15}$ Department of Clinical and Molecular Sciences, University ‘Politecnica delle Marche’, ia Tronto, 10/a, 60126, Ancona, Italy;<br>${ }^{16}$ Department of Medicine, Unit of General Medicine for the Study and Treatment of Hypertensive Disease, Policlinico GB Rossi, University of Verona, Piazzale L.A. Scuro, 10, 37134, Verona, Italy;<br>${ }^{17}$ Centro Fisiologia Clinica e Ipertensione, Ospedale Policlinico, Università Milano, Via Francesco Sforza, 35, 20122, Milan, Italy;<br>${ }^{18}$ Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Via Giuseppe Verdi, 8, 10124, Torino, Italy;<br>${ }^{19}$ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Unit of Nephrology and Hypertension, European Society of Hypertension Excellence Centre, University of Palermo, Piazza Marina, 61, 90133, Palermo, Italy;

[^0]${ }^{20}$ Clinical and Molecular Medicine Department, Cardiology Unit Sant'Andrea Hospital, Sapienza University of Rome, Via di Grottarossa, 1035/ 1039, 00189, Via di Grottarossa, 1035/ 1039, 00189, Rome, Italy;<br>${ }^{21}$ Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy;<br>${ }^{22}$ Department of Medical and Surgical Sciences, Faculty of Medicine, University of Bologna, Via Zamboni, 33, 40126, Bologna, Italy;<br>${ }^{23}$ Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK;<br>${ }^{24}$ Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London W6 8RP, UK; and<br>${ }^{25}$ IRCCS Neuromed, 86077 Pozzilli (Isernia), Italy.

## KEYWORDS

Hypertension;
Blood pressure;
Screening;
Treatment;
Control

Cardiovascular (CV) diseases are burdened by high mortality and morbidity, being responsible for half of the deaths in Europe. Although hypertension is recognized as the most important CV risk factor, hypertension awareness and blood pressure (BP) control are still unsatisfactory. In 2017, $30.6 \%$ of a $>10000$ individual sample who took part in the May Measurement Month (MMM) campaign in Italy was found to have high BP. To raise awareness on the hypertension issue and to report BP data on a nation-wide scale in Italy. In the frame of the MMM campaign, an opportunistic crosssectional survey of volunteers aged $\geq 18$ was carried out in May 2018. Blood pressure measurement, the definition of hypertension and statistical analysis followed the standard MMM protocol. Screenings were conducted in multiple sites by health care personnel. Among the 5554 people screened (females: 48.3\%, mean age $58 \pm 17$ years) mean BP was $127 / 77 \mathrm{mmHg}$, and after imputations, $1462(26.3 \%)$ participants were found to have high BP levels. Body mass index $>25$ was associated with higher systolic BP and diastolic BP (DBP), while diabetes was associated with high DBP only. Our data provide a nation-wide snapshot of BP control in a sample of individuals participating in a national health care campaign, and confirm the power of this kind of healthcare-related activities in reaching a significant number of people to raise awareness on health topics. The apparent positive trend in BP control compared to available data from other similar campaigns carried out during the past years needs to be confirmed with more methodologically robust studies.

## Introduction

Cardiovascular (CV) diseases (CVDs) are responsible for more than half of all deaths across Europe. Thanks to a combination of modifiable and unmodifiable factors, including but not limited to unhealthy lifestyle and improved survival to acute events, their prevalence is on the rise. ${ }^{1}$

In 2016, the Italian Agency of Statistics (ISTAT) reported a yearly incidence of 367 deaths due to CVDs per 100000 inhabitants, corresponding to a total of approximately 220200 deaths. Of these, 69653 were due to ischaemic heart disease, and 57230 to cerebrovascular diseases. ${ }^{2}$
The effectiveness of total CV risk reduction in preventing events is universally accepted ${ }^{3,4}$ and up to $80 \%$ of premature heart disease and stroke are considered preventable. ${ }^{5}$ Arterial hypertension, known as the silent killer, represents the most important independent risk factor for CVDs, ${ }^{6}$ with a reported prevalence in Italy ranging from $55 \%$ to $59 \%$ of the adult population, ${ }^{7}$ with target blood pressure (BP) values reportedly achieved in $<50 \%$ of known hypertensives. ${ }^{8}$ For this reason, the Italian Society of Hypertension has been active over many years in raising awareness in both the general population and health professionals on this issue, taking part each year for more than a decade in the World Hypertension Day activities, promoted by the World Hypertension League/International Society of Hypertension.

On these bases, taking part in the May Measurement Month (MMM) initiative ${ }^{9,10}$ was just the natural step forward, with the aim of reaching as many people as possible and of stimulating them to develop a more pro-active attitude towards management of their cardiovascular risk profile, in particular in relation to their BP levels. In 2017, thanks to the invaluable contribution of more than 300 investigators affiliated to the Italian Society of Hypertension and of the Italian Red Cross, which supported the initiative with logistics and personnel, we were able to reach more than 10000 people. ${ }^{11}$ In 2018, we decided to administer a more complete questionnaire, collecting data on anthropometric variables as well as on comorbidities, a choice which has allowed us to obtain more comprehensive information, but a the price of a lower number of subjects accepting to participate.

## Methods

MMM18 activities in Italy were co-ordinated by the Council of the Italian Society of Hypertension as in previous years. Informed consent was obtained for each participant onsite. No personal information was requested, as all forms were anonymously filled in. During the month of May 2018, 91 sites in Italy operated for a different number of days (from 1 to 5 days depending on the site), interviewing and measuring the BP of individuals aged 18 and over who decided


Figure 1 Mean blood pressure values in those with different cardiovascular risk factors compared to those without, from linear regression models adjusted for age and sex.
to stop by. A total estimated number of 200 volunteers were involved in the campaign. Blood pressure measuring stations were available inside hospitals and at crossroads, with the logistical support of the Italian Red Cross, both in cities and villages. All the staff had a training in health care and received specific training on BP measurements. Either doctors, nurses, paramedics, and medical students performed the BP recordings and administered an ad hoc created questionnaire. In addition, outdoor measurements were performed in walled gazebos, in order to keep the ambient temperature controlled and to allow seated rest of suitable duration before the measurement. All selected devices had been validated accordingly to the ESH-IP protocol and BP measurements were performed according to the European Society of Hypertension/European Society of Cardiology (ESH/ESC) 2018 guidelines. In brief, three consecutive measurements were collected in the sitting position, with back and arm supported, after a 5-min rest. Hypertension was defined as $B P>140 / 90 \mathrm{mmHg}$ (average of the 2 nd and 3 rd measurements) and/or evidence of treatment with antihypertensive medication. Furthermore, height and weight reported by the participants were recorded, alongside with the history of cardiovascular risk factors.

The study was bottom funded, i.e. each centre which decided to take part in the activity printed its own questionnaires and BP forms and then sent the hard copies to the core lab for data entry facilitated by optical character recognition technology. Data were centrally analysed by the MMM team in London with multiple imputation according to the standard analysis plan. ${ }^{9}$

## Results

Our sample consisted of 5554 participants (females: $48.3 \%$ ), aged $58 \pm 17$ years. The absolute number of
participants per age groups increased by each decade after 39 years old, reaching the maximum for the age group $>70$ years, which counted 1581 subjects, representing $28.5 \%$ of the whole sample.

Active smoking was reported by 825 subjects (14.9\%), diabetes by 446 ( $8.0 \%$ ), previous myocardial infarction by 399 (7.2\%), and previous stroke by 122 (2.2\%). Mean body mass index was $25.4 \pm 4.4$, with $47.3 \%$ of subjects being of normal weight or underweight and $49.3 \%$ overweight or obese (these data were not available in $3.4 \%$ of subjects).
Average BP (mean of reading 2 and 3 ) was $127 / 77 \mathrm{mmHg}$, with a proportion of hypertensives (as previously defined) after imputation of $26.3 \%$ out of the 5554 subjects screened.

Known hypertension ( $N=1692$, 30.5\%) was associated with higher systolic BP (SBP) and diastolic BP (DBP) ( $P<$ 0.0001 for both), whilst diabetes was associated with higher SBP only. Furthermore, patients who reported a previous myocardial infarction had lower DBP ( $P=0.026$ ). Accordingly, obesity (14\%) and overweight ( $35.3 \%$ ) status were associated with higher SBP and DBP ( $P<0.0001$ for all), whilst underweight status ( $2.8 \%$ ) was associated with lower SBP/DBP compared to normal weight ( $44.5 \%, P<$ 0.0001 for SBP, $P=0.002$ for DBP) (see Figure 1).

## Discussion

Our data, obtained through a cross-sectional survey, provide a contemporary update on BP values collected nationwide from a sample of the Italian population. As described, $26.3 \%$ of the screened individuals were found to be hypertensive, a proportion slightly lower than the one reported by our group in 2017 in the same frame of the MMM campaign ( $30.8 \%$ out of a sample of $>10000$ individuals), ${ }^{11}$ and in 2015, in a similar campaign conducted during the World

Hypertension Day ( $36 \%$ out of a sample of 8657 individuals). ${ }^{8}$ Similarly, the reported average BP values slightly but progressively decreased from $2015(133 / 80 \mathrm{mmHg})^{8}$ to $2017(130 / 78 \mathrm{mmHg})^{11}$ to $2018(127 / 77 \mathrm{mmHg})$. Although we recognize that the significance of these data, especially in terms of comparability from 1 year to the other, is weakened by a number of methodological limitations, typical of the 'street epidemiology' approach (including but not limited to sampling bias, incomplete sample characterization, environmental factors unaccountable for the lack of specific cut-off values for BP measured in such circumstances), they still appear encouraging. In fact, over the years many efforts have been made by the Italian Society of Hypertension aimed at raising awareness of hypertension and its complications, ${ }^{12}$ increasing early diagnosis and improving BP control. These efforts now seem to yield appreciable results. As per the other findings, they are generally consistent with available literature, including the relationship between body weight and BP, the increased prevalence of high BP values in diabetic patients, the gap observed between females and males BP, which narrows as age increases. ${ }^{3}$

By joining the MMM campaign, we have thus been able to reach a significant number of people, to measure their BP in a carefully standardized manner and to spread higher awareness on hypertension and its untoward consequences with the final goal of improving BP control (as shown by the progressive reduction in the average $B P$ levels we have recorded over the years) which might help to reduce CV morbidity and mortality.

## Supplementary material

Supplementary material is available at European Heart Journal Supplements online.

## Acknowledgements

The authors would like to thank all the local investigators, without whom this data collection would not have been possible and the Italian Red Cross for its support with volunteers and means (see Supplementary material online, Investigators list).

## Funding

For this campaign, we received semiautomatic sphygmomanometers from the MMM organizers, thanks to the unrestricted generosity of Omron HealthCare.

Conflict of interest: none declared.

## References

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 populationbased measurement studies with 19.1 million participants. Lancet 2017;389:37-55.
[2]. ISTAT-Salute e sanità. https://www.istat.it/it/salute-e-sanit\� \%A0 (21 March 2020).
[3]. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.
[4]. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269-1324.
[5]. WHO. Cardiovascular Disease-Data and Statistics. http://www. euro.who.int/en/health-topics/noncommunicable-diseases/cardio vascular-diseases/data-and-statistics (21 March 2020).
[6]. WHO. A Global Brief on Hypertension. Silent Killer, Global Public Health Crisis. 2013. http://www.who.int/cardiovascular_diseases/ publications/global_brief_hypertension/en/ (21 March 2020).
[7]. Tocci G, Muiesan ML, Parati G, Agabiti Rosei E, Ferri C, Virdis A, Pontremoli R, Mancia G, Borghi C, Volpe M; Working Group of the Italian Society of Hypertension (SIIA) and SIIA Foundation. Trends in prevalence, awareness, treatment, and control of blood pressure recorded from 2004 to 2014 during World Hypertension Day in Italy. J Clin Hypertens (Greenwich) 2016;18:551-556.
[8]. Torlasco C, Faini A, Makil E, Ferri C, Borghi C, Veglio F, Desideri G, Agabiti Rosei E, Ghiadoni L, Pauletto P, Pontremoli R, Stornello M, Tocci G, Galletti F, Trimarco B, Parati G. Cardiovascular risk and hypertension control in Italy. Data from the 2015 World Hypertension Day. Int J Cardiol 2017;243:529-532.
[9]. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, Kruger R, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP, Schutte AE, Tomaszewski M, Touyz R, Wang J-G, Weber MA, Poulter NR; MMM Investigators. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J 2019;40: 2006-2017.
[10]. Beaney T, Schutte AE, Tomaszewski M, Ariti C, Burrell LM, Castillo RR, Charchar FJ, Damasceno A, Kruger R, Lackland DT, Nilsson PM, Prabhakaran D, Ramirez AJ, Schlaich MP, Wang J, Weber MA, Poulter NR;MMM Investigators. May Measurement Month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob Health 2018;6:e736-e743.
[11]. Torlasco C, Faini A, Makil E, Bilo G, Pengo M, Beaney T, Xia X, Borghi C, Poulter NR, Tocci G, Galletti F, Desideri G, Veglio F, Ferri C, Parati G. Nation-wide hypertension screening in Italy: data from May Measurements Month 2017-Europe. Eur Heart J Suppl 2019; 21(Suppl D):D66-D70.
[12]. Torlasco C, Santini F, Liu X, Faini A, Parati G. Awareness of hypertension consequences is less than awareness of risk factors for hypertension. J Cardiovasc Med 2017; 18:563-565.

[^0]:    *Corresponding author. Tel: +39 02619112949, Fax: +3902619112956 , Email: gianfranco.parati@unimib.it

